## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

C#

1615

Date: September 1, 2006

M#

in re Patent Application of

1035-579 Atty Dkt.

Examiner: Not KNown

KURODA et al.

Serial No. 10/529,749

March 30.

HOLLOW PROTEIN NANO

AND DRUG USING THE SAME

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

TC/A.U.

Sir:

Title:

## RESPONSE TO NOTIFICATION TO COMPLY

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

## □ Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

minus highest number Total effective claims after amendment 10

x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$ (at least 20) =previously paid for 20

Independent claims after amendment minus highest number

x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$ previously paid for (at least 3) =

If proper multiple dependent claims now added for first time, (ignore improper); add

\$360.00 (1203)/\$180.00 (2203) \$

\$130.00 (1814)/\$65.00 (2814) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this

One Month Extension \$120.00 (1251)/\$60.00 (2251) paper and attachment(s) Two Month Extensions \$450.00 (1252)/\$225.00 (2252)

Three Month Extensions \$1020.00 (1253/\$510.00 (2253)

Four Month Extensions \$1590.00 (1254/\$795.00 (2254)

Five Month Extensions \$2160.00 (1255/\$1080.00 (2255) \$

Terminal disclaimer enclosed, add

☐ Applicant claims "small entity" status. Statement filed herewith

\$180.00 (1806) \$ 0.00 Rule 56 Information Disclosure Statement Filing Fee

\$40.00 (8021) \$ 0.00 Assignment Recording Fee

Other: COPY OF NOTIFICATION TO COMPLY; PAPER AND COMPUTER READABLE 0.00

FORM OF THE SEQUENCE LISTING

0.00 TOTAL FEE ENCLOSED \$

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

GRT:ap

NIXON & VANDERHYE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature:

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Voginia 22313-1450 www.uspto.gov

ATTY. DOCKET NO FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO Shunichi Kuroda 1035-579 10/829749 INTERNATIONAL APPLICATION NO. SEP 0 1 2006 PCT/JP03/15003 I.A. FILING DATE PRIORITY DATE 23117 Sea 11/22/2002 11/25/2003 NIXON & VANDERY 901 NORTH GLEBE ROAD 11TH FLOOR DOCKETED ARLINGTON, VA 22203 **CONFIRMATION NO. 1581** CLT/MATTER # **371 FORMALITIES LETTER** MAIL DATE \*OC000000020006195\* DUE DATE FINAL DEADLINE Date Mailed: 08/14/2006 DOCKETED BY

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)



PCEpy of this notice MUST be returned with the response.

FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

PART 1 - ATTORNEY/APPLICANT COPY

	ARTITATION	ATTY, DOCKET NO.
U.S. APPLICATION NUMBER NO. 10/529,749	INTERNATIONAL APPLICATION NO. PCT/JP03/15003	1035-579

FORM PCT/DO/EO/922 (371 Formalities Notice)